newsfilter
← Latest News
Earnings Call Transcripts·

Jefferies Global Healthcare Conference in London - EUPRAXIA PHARMACEUTICALS INC

  • Financial Performance:

    • Company maintains a cash runway extending to Q3 2028 based on current cash and short-term investments.
    • Estimated incremental capital requirement of approximately $125 million is needed to complete Phase 3 trials and achieve NDA submission.
    • Current use of proceeds includes funding the completion of the current EOE Phase 2 trial and the execution of a Phase 2 trial for benign esophageal strictures.
    • No revenue, profit margins, or cash flow from product sales reported as the company remains pre-revenue in the clinical development stage.
  • Guidance and Future Outlook:

    • Interim data analysis from the EOE Phase 2b trial (combining top two doses vs. placebo) expected within the next several weeks, specifically targeting results for 60 patients at 24 weeks and 20 patients at 52 weeks.
    • End-of-Phase 2 meeting with regulators anticipated in the first part of 2027 to determine the path forward to Phase 3.
    • Market size for eosinophilic esophagitis (EOE) projected to exceed 1 million patients in the US by 2030, with current diagnosed patients reaching 724,000 by mid-2026.
    • Product launch strategy aims for a once-annual dosing schedule, ideally administered at 12 months prior to symptom recurrence.
    • Protocol amended to extend patient follow-up to two years to better determine optimal timing for a potential second dose.
  • Business Segments and Product Lines:

    • Primary focus is Eupraxia's "Diffusphere" platform delivering fluticasone propionate via submucosal injection for Eosinophilic Esophagitis (EOE).
    • Clinical results from Part 1 show 64% of patients in clinical remission (stratified by Straumann Dysphagia Index) at 52 weeks following a single injection.
    • Secondary target identified: Benign esophageal strictures, a market of ~500,000 US patients currently managed by balloon dilation and temporary steroid injections, where the company's product could offer a longer-duration alternative.
    • No new product launches reported; however, the company is preparing to address unmet needs in fibrosis reversal and strictures resolution beyond the approved EOE indication.
  • Market and Competitive Landscape:

    • Addresses a market gap where standard care (PPIs, oral steroids, biologics) suffers from poor long-term compliance, safety issues (e.g., oral candidiasis), or inability to reverse fibrosis.
    • Competitive landscape includes approved biologics (taking ~8% market share) and oral steroids, but management estimates ~45% of the addressable market remains unaddressed.
    • Differentiation strategy relies on the product being a medical benefit (not pharmacy benefit), allowing for increased procedural fees, and targeting physicians who perform the injections during routine endoscopies.
    • Claims analysis by IQVIA indicates a steady growth rate of ~72,000 new diagnostic codes per year in the US.
  • Risks and Challenges:

    • Interim data analysis is not powered for statistical significance on all endpoints (symptoms, histology, endoscopy) due to sample size; strong directional trends are expected rather than definitive statistical wins.
    • The disease pathology (fibrosis) is progressive, and management must validate the durability of fibrosis reversal over the 2-year follow-up period.
    • Regulatory risk exists regarding the acceptance of surrogate endpoints (EOHSS) and patient-reported outcomes (SDI/DSQ) in the blinded Phase 2b data.
    • Potential need for a $125 million capital raise to sustain the Phase 3 program and NDA filing.
  • Management Commentary and Tone:

    • CEO James Helliwell (physician background) conveyed high confidence, emphasizing the unique "zero-order kinetics" of the drug delivery and the clinical disconnect between eosinophil counts and actual patient symptom relief.
    • Tone was enthusiastic regarding the speed of patient recruitment (twice the rate of other trials) and the anecdotal reports of patients seeking retreatment due to symptom relief lasting beyond 12 months.
    • Management expressed strong conviction that their product targets the root cause (fibrosis and broad inflammation) unlike competitors that focus solely on eosinophil reduction.
    • Cautioned that while Phase 2b interim data is not registrational, hitting statistical significance would be a significant milestone.
  • Analyst Questions and Answers:

    • No formal Q&A session occurred as the CEO concluded the presentation before time expired.
    • Management invited investors to connect directly after the call for further discussions.
  • Other Key Points:

    • The EOE diagnostic code (K20.0) is no longer considered an "orphan" indication by the FDA as of late 2023.
    • Safety profile has been robust across >3,000 individual injections with zero procedure-related complications (perforation, abscesses) and no cases of oropharyngeal candidiasis or adrenal suppression.
    • The company utilizes the standard-of-care endoscopy procedure, adding only ~10 minutes to the physician's workflow, facilitating rapid adoption by gastroenterologists.
    • Data suggests a strong correlation between EOHSS score reduction (inflammation and fibrosis) and clinical symptom improvement, unlike other EOE therapies where eosinophil count reduction did not correlate with clinical outcomes.
Company
EUPRAXIA PHARMACEUTICALS INC
Keywords
EUPRAXIA PHARMACEUTICALS INC